Lupin announces licensing deal for ranibizumab biosimilar. Posted by Able on August 11, 2025 Get link Facebook X Pinterest Email Other Apps The company announced in a press release that it has partnered with Switzerland’s Sandoz Group AG to market and commercialise its biosimilar Ranibizumab in multiple regions. Comments
Comments
Post a Comment